Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour
The effects of a new titanocene compound with an ansa ligand in the cyclopentadienyl rings, the 1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride (TITANOCENE X), on the growth and differentiation of granulocyte–macrophage progenitor cells [colony-forming u...
Gespeichert in:
Veröffentlicht in: | European journal of pharmacology 2006-03, Vol.534 (1), p.264-270 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 270 |
---|---|
container_issue | 1 |
container_start_page | 264 |
container_title | European journal of pharmacology |
container_volume | 534 |
creator | Valadares, Marize C. Ramos, Aline L. Rehmann, Franz-Josef K. Sweeney, Nigel J. Strohfeldt, Katja Tacke, Matthias Queiroz, Mary L.S. |
description | The effects of a new titanocene compound with an ansa ligand in the cyclopentadienyl rings, the 1,2-di(cyclopentadienyl)-1,2-di(
p-
N,
N-dimethylaminophenyl)-ethanediyl] titanium dichloride (TITANOCENE X), on the growth and differentiation of granulocyte–macrophage progenitor cells [colony-forming unit-granulocyte–macrophage (CFU-GM)] and Natural killer (NK) cell activity in Ehrlich's ascites tumour (EAT)-bearing mice were studied. Myelosuppression concomitant with increased numbers of spleen CFU-GM was observed in tumour-bearing mice. Treatment of these animals with TITANOCENE X (2.5–50
mg/kg/day) produced an increase in myelopoiesis, in a dose-dependent manner, and reduced spleen colony formation. In addition, the treatment of EAT-bearing mice with 3
doses of 20 or 50
mg/kg TITANOCENE X restored to normal values the reduced Natural killer cell function observed during tumour growth. In parallel, TITANOCENE X prolonged, in a dose-dependent manner, the survival of mice inoculated with Ehrlich's ascites tumour. The highest dose of 50
mg/kg prolonged in 50% the survival time of EAT-bearing mice, compared to non-treated tumour-bearing controls. In comparison with previous results from our laboratory addressing the effects of titanocenes on haematopoiesis, we observed with TITANOCENE X a similar effective profile as for bis(cyclopentadienyl) dithiocyanate titanium(IV), being both less effective than di(cyclopentadienyl) dichloro titanium(IV), since the latter not only prolonged, but also increased the rate of survival. These differences in efficacy may be due to the nature of the
ansa-cyclopentadienyl ligand used in TITANOCENE X, since the C
2 bridge between the two cyclopentadienyl groups will increase the hydrolytic stability by an organometallic chelate effect. Also, the introduction of two dimethylamino substituents increases the water solubility of TITANOCENE X when compared to titanocene dichloride itself. |
doi_str_mv | 10.1016/j.ejphar.2006.01.056 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67735874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299906000884</els_id><sourcerecordid>67735874</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-1d9531ee3710d1bb8d560bea7986f330e42d369ccbbd7d0b2bc2af3cc25a66813</originalsourceid><addsrcrecordid>eNp9kctq3jAQhU1paf6kfYNStOkNYleSLdneFEJILxDSTbsqRcjSuNaPbDmSHOqHybtWwYbsuhox881hdE6WvSK4IJjwj8cCjvMgfUEx5gUmBWb8SXYgTd3muCb0aXbAmFQ5bdv2JDsN4YgxZi1lz7MTwhkpCeaH7P5iiiYuo1s8kiqaOxNX5Hr0i5zTXJv3alXWzTBFqQ1Mq_2Q7wM05-jmHN2k9whxWK0czeTmYYNSR06gzWp_o6QvJ7OMSBs1WOeNBmQm9Bcm98fLPoJGV4O3afguIBmUiRDQdtKL7FkvbYCXez3Lfn6--nH5Nb_-_uXb5cV1rsoWx5zolpUEoKwJ1qTrGs047kDWbcP7ssRQUV3yVqmu07XGHe0UlX2pFGWS84aUZ9nbTXf27naBEMVoggJr0yfcEgSv65I1dZXAagOVdyF46MXszSj9KggWD7GIo9hiEQ-xCExEiiWtvd71l24E_bi055CANzuQDJC293JSJjxyNWsorVjiPm0cJDfuDHiR_IJJJas9qCi0M_-_5B-Ela91</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67735874</pqid></control><display><type>article</type><title>Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Valadares, Marize C. ; Ramos, Aline L. ; Rehmann, Franz-Josef K. ; Sweeney, Nigel J. ; Strohfeldt, Katja ; Tacke, Matthias ; Queiroz, Mary L.S.</creator><creatorcontrib>Valadares, Marize C. ; Ramos, Aline L. ; Rehmann, Franz-Josef K. ; Sweeney, Nigel J. ; Strohfeldt, Katja ; Tacke, Matthias ; Queiroz, Mary L.S.</creatorcontrib><description>The effects of a new titanocene compound with an ansa ligand in the cyclopentadienyl rings, the 1,2-di(cyclopentadienyl)-1,2-di(
p-
N,
N-dimethylaminophenyl)-ethanediyl] titanium dichloride (TITANOCENE X), on the growth and differentiation of granulocyte–macrophage progenitor cells [colony-forming unit-granulocyte–macrophage (CFU-GM)] and Natural killer (NK) cell activity in Ehrlich's ascites tumour (EAT)-bearing mice were studied. Myelosuppression concomitant with increased numbers of spleen CFU-GM was observed in tumour-bearing mice. Treatment of these animals with TITANOCENE X (2.5–50
mg/kg/day) produced an increase in myelopoiesis, in a dose-dependent manner, and reduced spleen colony formation. In addition, the treatment of EAT-bearing mice with 3
doses of 20 or 50
mg/kg TITANOCENE X restored to normal values the reduced Natural killer cell function observed during tumour growth. In parallel, TITANOCENE X prolonged, in a dose-dependent manner, the survival of mice inoculated with Ehrlich's ascites tumour. The highest dose of 50
mg/kg prolonged in 50% the survival time of EAT-bearing mice, compared to non-treated tumour-bearing controls. In comparison with previous results from our laboratory addressing the effects of titanocenes on haematopoiesis, we observed with TITANOCENE X a similar effective profile as for bis(cyclopentadienyl) dithiocyanate titanium(IV), being both less effective than di(cyclopentadienyl) dichloro titanium(IV), since the latter not only prolonged, but also increased the rate of survival. These differences in efficacy may be due to the nature of the
ansa-cyclopentadienyl ligand used in TITANOCENE X, since the C
2 bridge between the two cyclopentadienyl groups will increase the hydrolytic stability by an organometallic chelate effect. Also, the introduction of two dimethylamino substituents increases the water solubility of TITANOCENE X when compared to titanocene dichloride itself.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2006.01.056</identifier><identifier>PMID: 16513106</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Abdomen ; Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Carcinoma, Ehrlich Tumor - drug therapy ; Carcinoma, Ehrlich Tumor - immunology ; Carcinoma, Ehrlich Tumor - pathology ; Cell Proliferation ; Colony-Forming Units Assay ; Dose-Response Relationship, Drug ; Gastroenterology. Liver. Pancreas. Abdomen ; Haematopoiesis ; Hematopoietic Stem Cells - drug effects ; Hematopoietic Stem Cells - pathology ; Killer Cells, Natural - drug effects ; Killer Cells, Natural - immunology ; Male ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Myelopoiesis - drug effects ; Natural killer ; Neoplasm Transplantation ; Organometallic Compounds - pharmacology ; Organometallic Compounds - therapeutic use ; Other diseases. Semiology ; Pharmacology. Drug treatments ; Titanocene ; Tumour</subject><ispartof>European journal of pharmacology, 2006-03, Vol.534 (1), p.264-270</ispartof><rights>2006 Elsevier B.V.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-1d9531ee3710d1bb8d560bea7986f330e42d369ccbbd7d0b2bc2af3cc25a66813</citedby><cites>FETCH-LOGICAL-c390t-1d9531ee3710d1bb8d560bea7986f330e42d369ccbbd7d0b2bc2af3cc25a66813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0014299906000884$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17582245$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16513106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Valadares, Marize C.</creatorcontrib><creatorcontrib>Ramos, Aline L.</creatorcontrib><creatorcontrib>Rehmann, Franz-Josef K.</creatorcontrib><creatorcontrib>Sweeney, Nigel J.</creatorcontrib><creatorcontrib>Strohfeldt, Katja</creatorcontrib><creatorcontrib>Tacke, Matthias</creatorcontrib><creatorcontrib>Queiroz, Mary L.S.</creatorcontrib><title>Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>The effects of a new titanocene compound with an ansa ligand in the cyclopentadienyl rings, the 1,2-di(cyclopentadienyl)-1,2-di(
p-
N,
N-dimethylaminophenyl)-ethanediyl] titanium dichloride (TITANOCENE X), on the growth and differentiation of granulocyte–macrophage progenitor cells [colony-forming unit-granulocyte–macrophage (CFU-GM)] and Natural killer (NK) cell activity in Ehrlich's ascites tumour (EAT)-bearing mice were studied. Myelosuppression concomitant with increased numbers of spleen CFU-GM was observed in tumour-bearing mice. Treatment of these animals with TITANOCENE X (2.5–50
mg/kg/day) produced an increase in myelopoiesis, in a dose-dependent manner, and reduced spleen colony formation. In addition, the treatment of EAT-bearing mice with 3
doses of 20 or 50
mg/kg TITANOCENE X restored to normal values the reduced Natural killer cell function observed during tumour growth. In parallel, TITANOCENE X prolonged, in a dose-dependent manner, the survival of mice inoculated with Ehrlich's ascites tumour. The highest dose of 50
mg/kg prolonged in 50% the survival time of EAT-bearing mice, compared to non-treated tumour-bearing controls. In comparison with previous results from our laboratory addressing the effects of titanocenes on haematopoiesis, we observed with TITANOCENE X a similar effective profile as for bis(cyclopentadienyl) dithiocyanate titanium(IV), being both less effective than di(cyclopentadienyl) dichloro titanium(IV), since the latter not only prolonged, but also increased the rate of survival. These differences in efficacy may be due to the nature of the
ansa-cyclopentadienyl ligand used in TITANOCENE X, since the C
2 bridge between the two cyclopentadienyl groups will increase the hydrolytic stability by an organometallic chelate effect. Also, the introduction of two dimethylamino substituents increases the water solubility of TITANOCENE X when compared to titanocene dichloride itself.</description><subject>Abdomen</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Ehrlich Tumor - drug therapy</subject><subject>Carcinoma, Ehrlich Tumor - immunology</subject><subject>Carcinoma, Ehrlich Tumor - pathology</subject><subject>Cell Proliferation</subject><subject>Colony-Forming Units Assay</subject><subject>Dose-Response Relationship, Drug</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Haematopoiesis</subject><subject>Hematopoietic Stem Cells - drug effects</subject><subject>Hematopoietic Stem Cells - pathology</subject><subject>Killer Cells, Natural - drug effects</subject><subject>Killer Cells, Natural - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Myelopoiesis - drug effects</subject><subject>Natural killer</subject><subject>Neoplasm Transplantation</subject><subject>Organometallic Compounds - pharmacology</subject><subject>Organometallic Compounds - therapeutic use</subject><subject>Other diseases. Semiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Titanocene</subject><subject>Tumour</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctq3jAQhU1paf6kfYNStOkNYleSLdneFEJILxDSTbsqRcjSuNaPbDmSHOqHybtWwYbsuhox881hdE6WvSK4IJjwj8cCjvMgfUEx5gUmBWb8SXYgTd3muCb0aXbAmFQ5bdv2JDsN4YgxZi1lz7MTwhkpCeaH7P5iiiYuo1s8kiqaOxNX5Hr0i5zTXJv3alXWzTBFqQ1Mq_2Q7wM05-jmHN2k9whxWK0czeTmYYNSR06gzWp_o6QvJ7OMSBs1WOeNBmQm9Bcm98fLPoJGV4O3afguIBmUiRDQdtKL7FkvbYCXez3Lfn6--nH5Nb_-_uXb5cV1rsoWx5zolpUEoKwJ1qTrGs047kDWbcP7ssRQUV3yVqmu07XGHe0UlX2pFGWS84aUZ9nbTXf27naBEMVoggJr0yfcEgSv65I1dZXAagOVdyF46MXszSj9KggWD7GIo9hiEQ-xCExEiiWtvd71l24E_bi055CANzuQDJC293JSJjxyNWsorVjiPm0cJDfuDHiR_IJJJas9qCi0M_-_5B-Ela91</recordid><startdate>20060318</startdate><enddate>20060318</enddate><creator>Valadares, Marize C.</creator><creator>Ramos, Aline L.</creator><creator>Rehmann, Franz-Josef K.</creator><creator>Sweeney, Nigel J.</creator><creator>Strohfeldt, Katja</creator><creator>Tacke, Matthias</creator><creator>Queiroz, Mary L.S.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060318</creationdate><title>Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour</title><author>Valadares, Marize C. ; Ramos, Aline L. ; Rehmann, Franz-Josef K. ; Sweeney, Nigel J. ; Strohfeldt, Katja ; Tacke, Matthias ; Queiroz, Mary L.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-1d9531ee3710d1bb8d560bea7986f330e42d369ccbbd7d0b2bc2af3cc25a66813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Abdomen</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Ehrlich Tumor - drug therapy</topic><topic>Carcinoma, Ehrlich Tumor - immunology</topic><topic>Carcinoma, Ehrlich Tumor - pathology</topic><topic>Cell Proliferation</topic><topic>Colony-Forming Units Assay</topic><topic>Dose-Response Relationship, Drug</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Haematopoiesis</topic><topic>Hematopoietic Stem Cells - drug effects</topic><topic>Hematopoietic Stem Cells - pathology</topic><topic>Killer Cells, Natural - drug effects</topic><topic>Killer Cells, Natural - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Myelopoiesis - drug effects</topic><topic>Natural killer</topic><topic>Neoplasm Transplantation</topic><topic>Organometallic Compounds - pharmacology</topic><topic>Organometallic Compounds - therapeutic use</topic><topic>Other diseases. Semiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Titanocene</topic><topic>Tumour</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valadares, Marize C.</creatorcontrib><creatorcontrib>Ramos, Aline L.</creatorcontrib><creatorcontrib>Rehmann, Franz-Josef K.</creatorcontrib><creatorcontrib>Sweeney, Nigel J.</creatorcontrib><creatorcontrib>Strohfeldt, Katja</creatorcontrib><creatorcontrib>Tacke, Matthias</creatorcontrib><creatorcontrib>Queiroz, Mary L.S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valadares, Marize C.</au><au>Ramos, Aline L.</au><au>Rehmann, Franz-Josef K.</au><au>Sweeney, Nigel J.</au><au>Strohfeldt, Katja</au><au>Tacke, Matthias</au><au>Queiroz, Mary L.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2006-03-18</date><risdate>2006</risdate><volume>534</volume><issue>1</issue><spage>264</spage><epage>270</epage><pages>264-270</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>The effects of a new titanocene compound with an ansa ligand in the cyclopentadienyl rings, the 1,2-di(cyclopentadienyl)-1,2-di(
p-
N,
N-dimethylaminophenyl)-ethanediyl] titanium dichloride (TITANOCENE X), on the growth and differentiation of granulocyte–macrophage progenitor cells [colony-forming unit-granulocyte–macrophage (CFU-GM)] and Natural killer (NK) cell activity in Ehrlich's ascites tumour (EAT)-bearing mice were studied. Myelosuppression concomitant with increased numbers of spleen CFU-GM was observed in tumour-bearing mice. Treatment of these animals with TITANOCENE X (2.5–50
mg/kg/day) produced an increase in myelopoiesis, in a dose-dependent manner, and reduced spleen colony formation. In addition, the treatment of EAT-bearing mice with 3
doses of 20 or 50
mg/kg TITANOCENE X restored to normal values the reduced Natural killer cell function observed during tumour growth. In parallel, TITANOCENE X prolonged, in a dose-dependent manner, the survival of mice inoculated with Ehrlich's ascites tumour. The highest dose of 50
mg/kg prolonged in 50% the survival time of EAT-bearing mice, compared to non-treated tumour-bearing controls. In comparison with previous results from our laboratory addressing the effects of titanocenes on haematopoiesis, we observed with TITANOCENE X a similar effective profile as for bis(cyclopentadienyl) dithiocyanate titanium(IV), being both less effective than di(cyclopentadienyl) dichloro titanium(IV), since the latter not only prolonged, but also increased the rate of survival. These differences in efficacy may be due to the nature of the
ansa-cyclopentadienyl ligand used in TITANOCENE X, since the C
2 bridge between the two cyclopentadienyl groups will increase the hydrolytic stability by an organometallic chelate effect. Also, the introduction of two dimethylamino substituents increases the water solubility of TITANOCENE X when compared to titanocene dichloride itself.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>16513106</pmid><doi>10.1016/j.ejphar.2006.01.056</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2999 |
ispartof | European journal of pharmacology, 2006-03, Vol.534 (1), p.264-270 |
issn | 0014-2999 1879-0712 |
language | eng |
recordid | cdi_proquest_miscellaneous_67735874 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Abdomen Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Ehrlich Tumor - drug therapy Carcinoma, Ehrlich Tumor - immunology Carcinoma, Ehrlich Tumor - pathology Cell Proliferation Colony-Forming Units Assay Dose-Response Relationship, Drug Gastroenterology. Liver. Pancreas. Abdomen Haematopoiesis Hematopoietic Stem Cells - drug effects Hematopoietic Stem Cells - pathology Killer Cells, Natural - drug effects Killer Cells, Natural - immunology Male Medical sciences Mice Mice, Inbred BALB C Myelopoiesis - drug effects Natural killer Neoplasm Transplantation Organometallic Compounds - pharmacology Organometallic Compounds - therapeutic use Other diseases. Semiology Pharmacology. Drug treatments Titanocene Tumour |
title | Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di( p- N, N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A46%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antitumour%20activity%20of%20%5B1,2-di(cyclopentadienyl)-1,2-di(%20p-%20N,%20N-dimethylaminophenyl)-ethanediyl%5D%20titanium%20dichloride%20in%20xenografted%20Ehrlich's%20ascites%20tumour&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Valadares,%20Marize%20C.&rft.date=2006-03-18&rft.volume=534&rft.issue=1&rft.spage=264&rft.epage=270&rft.pages=264-270&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/j.ejphar.2006.01.056&rft_dat=%3Cproquest_cross%3E67735874%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67735874&rft_id=info:pmid/16513106&rft_els_id=S0014299906000884&rfr_iscdi=true |